Table 2 Disease characteristics of cases with B-cell depletion therapy prior to COVID-19.

Indication for B-cell depletion therapy, no. (%)

 Benign hematological disorder^a

 Malignancy^b

 Neurologic disorder^c

 Rheumatologic disorder^d

 Solid organ transplant^e

Type of B-cell depletion medication, no. (%)

 Rituximab

 Ocrelizumab

Most recent B-cell depletion medication prior to COVID-19 onset, no. (%)

 <  = 90 days

 91 days–365 days

 > 365 days